Are you a US Healthcare Professional?

The content on this page is intended for US healthcare professionals only. By clicking "Yes," you confirm that you are a licensed healthcare professional in the United States.

To report an adverse event or for medical inquiries,
please contact CorMedix at medinfo@cormedix.com
  • Home >
  • Medical Affairs

Publications

Browse CorMedix Therapeutics sponsored and supported publications organized by product.

 See full Prescribing Information

Manuscripts

Review Articles

Taurolidine/Heparin Lock Solution and Catheter-Related Bloodstream Infection in Hemodialysis: A Randomized, Double-Blind, Active-Control, Phase 3 Study.
Clin J Am Soc Nephrol. 2023;18(11):1446-1455.
In Vitro Activity of Taurolidine Against Clinical Candida auris Isolates: Relevance to Catheter-Related Bloodstream Infections.
Antimicrob Agents Chemother. 2024;68(7):e00381-24.

Presentations

ACCP 2025

In Vitro Checkerboard Analysis of Combined Taurolidine and Chlorhexidine Acetate Against a Panel of Gram-Positive and Gram-Negative Bacteria. Poster 913.

ASN Kidney Week 2024

Hospital Admissions for Bloodstream Infections Acquired During Outpatient Hemodialysis Through a Central Venous Catheter (HD-CVC): Patient Population and Selected Outcomes. Poster FR-PO547.

SHEA Spring 2024

In Vitro Antimicrobial Activity of Taurolidine Against Isolates Associated with Catheter-Related Bloodstream Infections. Poster 130.
Impacts of Hospital-Acquired Bloodstream Infections in Patients Undergoing Hemodialysis Through a Central Venous Catheter. Poster 264.

MAD-ID 2024

In Vitro Activity of Taurolidine Against Clinical Candida auris Isolates; Relevance to Catheter-Related Bloodstream Infections. Poster 45.

IDWeek 2023

In Vitro Antimicrobial Activity of Taurolidine Against Candida auris Bloodstream Isolates from Global Sources. Poster 2117.

 See full Prescribing Information

Manuscripts

Registrational and Pivotal Trial Data

Clinical and Mycological Outcomes of Candidaemia and/or Invasive Candidiasis by Candida spp. and Antifungal Susceptibility: Pooled Analyses of Two Randomized Trials of Rezafungin Versus Caspofungin.
Clin Microbiol Infect. 2025 Feb;31(2):250-257.
Length of Hospital and Intensive Care Unit Stay in Patients with Invasive Candidiasis and/or Candidemia Treated with Rezafungin: A Pooled Analysis of Two Randomised Controlled Trials.
Crit Care. 2024 Nov 11;28(1):361.
Rezafungin Versus Caspofungin for Patients with Candidaemia or Invasive Candidiasis in the Intensive Care Unit: Pooled Analyses of the ReSTORE and STRIVE Randomised Trials.
Crit Care. 2024 Oct 28;28(1):348.
Outcomes by Candida spp. in the ReSTORE Phase 3 Trial of Rezafungin Versus Caspofungin for Candidemia and/or Invasive Candidiasis.
Antimicrob Agents Chemother. 2024;68(5):e0158423.
Efficacy and Safety of Rezafungin and Caspofungin in Candidaemia and Invasive Candidiasis: Pooled Data from Two Prospective Randomised Controlled Trials.
Lancet Infect Dis. 2024 Mar;24(3):319-328.
Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study.
Clin Infect Dis. 2024;79(3):672-681.
Rezafungin Versus Caspofungin for Treatment Of Candidaemia and Invasive Candidiasis (ReSTORE): A Multicenter, Double-Blind, Double-Dummy, Randomised Phase 3 Trial.
Lancet. 2023;401:49-59.
Rezafungin Versus Caspofungin in A Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial.
Clin Infect Dis. 2021;73(11):e3647-55.

In Vitro Microbiology and Pharmacology Studies

Activity of Rezafungin Against Echinocandin Non–Wild Type Candida glabrata Clinical Isolates from a Global Surveillance Program.
Open Forum Infect Dis. 2025 Mar 3;12(3):ofae702.
Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects.
Pharmacotherapy. 2024 Jun;44(6):435-443.
Population Pharmacokinetic Modeling and Target Attainment Analyses of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis.
Antimicrob Agents Chemother. 2023 Dec 14;67(12):e0091623.
Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations.
Microbiol Spectr. 2023;11(3):e0133923.
Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections.
Antimicrob Agents Chemother. 2021;65(11):e0084221.
Lack of Effect of Rezafungin on QT/Qtc Interval in Healthy Subjects.
Clin Pharmacol Drug Dev. 2020;9(4):456-465.
In Vitro Activity of Rezafungin Against Common and Rare Candida Species and Saccharomyces cerevisiae.
J Antimicrob Chemother. 2019;74(12):3505-3510.
Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data.
Antimicrob Agents Chemother. 2018;62(6):e02603-17.
Metabolism, Excretion, and Mass Balance of [14C]-Rezafungin in Animals and Humans.
Antimicrob Agents Chemother. 2018;66(1):e0139021.
Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults.
Antimicrob Agents Chemother. 2017;61(2):e01627-16.

Review Articles

Activity of Rezafungin Against Candida auris.
J Antimicrob Chemother. 2025 Apr 30:dkaf124.
Rezafungin in Special Populations with Candidaemia and/or Invasive Candidiasis.
J Infect. 2025 Feb 5:106435.
Rezafungin: First Approval.
Drugs. 2023;83(9):833-840.

Presentations

ESCMID Global 2025

Resolution of Clinical Signs in Adults with Invasive Candidiasis and/or Candidaemia Treated with Rezafungin or Caspofungin: ReSTORE and STRIVE Trial Pooled Analysis. Poster.
Clinical Outcomes with Rezafungin or Caspofungin in Adults with Invasive Infections Due to Non-albicans Candida: Pooled Analysis from STRIVE and ReSTORE Trials (Including Extension Phase Data). Poster P2951.

IDWeek 2024

Week One Outcomes of Rezafungin vs Caspofungin Treatment for Candidemia and Invasive Candidiasis (CIC): Pooled Analysis of Two Randomized Trials Exploring Optimal Echinocandin Duration. Poster 1034.

ESCMID Global 2024

Treatment outcomes with rezafungin and caspofungin in adults with invasive candidiasis and/or candidaemia who had received no prior antifungal therapy: ReSTORE trial subgroup analysis. Poster 2977.

IDWeek 2023

Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program. Poster 2115.
Activity of Rezafungin against Echinocandin-Non-wild type C. glabrata Clinical Isolates from the Rezafungin Surveillance Program (2014-2021). Oral Presentation.

MAD-ID 2023

Healthcare Resource Utilization among Hospitalized Patients with Candidemia and Invasive Candidiasis without Candidemia who Received Definitive Treatment with an Echinocandin Across United States (US) Hospitals. Poster 44E.

ECCMID 2023

All-Cause and Attributable Mortality in Invasive Candidiasis and/or Candidaemia with Rezafungin and Caspofungin Treatment: Outcomes from the Restore Trial. Oral Presentation.
Safety Outcomes with Rezafungin and Caspofungin in the Treatment of Candidaemia And/Or Invasive Candidiasis: Phase 3 Data from the Restore Trial. Poster 2061.
Treatment Outcomes in Candidaemia and/or Invasive Candidiasis among Patients Receiving Rezafungin or Caspofungin While the Fungal Culture Was Still Positive. Poster 2063.
Treatment Outcomes with Rezafungin and Caspofungin in People Aged 65 Years and Above with Candidaemia And/Or Invasive Candidiasis: Integrated Analysis of Pooled Phase 2 And Phase 3 Data. ePoster.
Rezafungin and Caspofungin Treatment Response in Candidaemia/Invasive Candidiasis by Baseline Candida Species: Analysis of Pooled Phase 2 and Phase 3 Results. Poster 2048.

IDWeek 2022

Outcomes by Baseline Pathogen and Susceptibility in the ReSTORE Phase 3 Trial of Rezafungin Once Weekly Compared with Caspofungin Once Daily in Patients with Candidemia and/or Invasive Candidiasis. Poster 231.
Assessment of The Proportion of Hospitalized Patients with Candidemia and Invasive Candidiasis without Candidemia who Received an Echinocandin and Were Potentially Eligible for an Earlier Hospital Discharge. Poster 468.
Healthcare Resource Utilization among Hospitalized Patients with Candidemia and Invasive Candidiasis without Candidemia who Received Definitive Treatment with an Echinocandin Across United States (US) Hospitals. Poster 469.
Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA). Poster 592.
Coadministration of Rezafungin Does Not Impact the Pharmacokinetics of Cyclosporine, Ibrutinib, Mycophenolate Mofetil, or Venetoclax. Poster 1694.

ECCMID 2021

Analysis of Safety from STRIVE Phase 2 Trial of Rezafungin Treatment of Candidemia and/or Invasive Candidiasis: Assessment of Adverse Events and Laboratory Values. Poster 1672.

IDWeek 2020

Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin. Poster 1284.

 See full Prescribing Information

Manuscripts

Registrational and Pivotal Trial Data

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
JAMA. 2018;319(8):788-799.
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.
Infect Dis Ther. 2018;7(4):439-455.
Efficacy and Safety of Meropenem-Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis.
Adv Ther. 2019;36(7):1771-1777.
Clinical Outcomes of Patient Subgroups in the TANGO II Study.
Infect Dis Ther. 2021;10(1):35-46.

In Vitro Microbiology and Pharmacology Studies

Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates.
Microbiol Spectr. 2023;11(1):e0450722.
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
Antimicrob Agents Chemother. 2022;66(12):e0213021.
Meropenem-vaborbactam activity against carbapenem-resistant Enterobacterales isolates collected in U.S. hospitals during 2016 to 2018.
Antimicrob Agents Chemother. 2020;64(3):e02177-19.
In vitro Evaluation of Meropenem-Vaborbactam Against Clinical CRE Isolates at a Tertiary Care Center with Low KPC-Mediated Carbapenem Resistance.
Diagn Microbiol Infect Dis. 2019;93(3):258-260.
Pharmacokinetics/Pharmacodynamics of Vaborbactam, A Novel Beta-Lactamase Inhibitor, In Combination with Meropenem.
Antimicrob Agents Chemother. 2018;63(1):e01659-18.
In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae.
Antimicrob Agents Chemother. 2017;62(1):e01904-17.
Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model.
Antimicrob Agents Chemother. 2018;62(2):e01969-17.

Review Articles

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
Infect Dis Ther. 2020;9(4):769-784.

Real-World Studies and Analyses

Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.
Clin Infect Dis. 2023 Jul 18:ciad428.

Presentations

ASM Microbe 2017

Clinical Outcomes with Meropenem-Vaborbactam (M-V) by Extended-Spectrum β-Lactamase (ESBL) Production in TANGO 1, a Phase 3 Randomized Trial vs Piperacillin-Tazobactam (P-T). Poster 305.
Meropenem-Vaborbactam (M-V): Clinical Outcomes by Bacteremia Status in Phase 3 Randomized, Double-Blind Trial in cUTIs (TANGO I). Poster 304.

IDWeek 2017

Meropenem-Vaborbactam (VABOMERE) vs. Piperacillin-Tazobactam in TANGO I (A Phase 3, Randomized, Double-Blind Trial): Outcomes by Baseline MIC in Adults with cUTI or AP. Poster 1866.

 See full Prescribing Information for KIMYRSA®
 See full Prescribing Information for ORBACTIV®

Manuscripts

Registrational and Pivotal Trial Data

Kimyrsa, an Oritavancin-Containing Product: Clinical Study and Review of Properties.
Open Forum Infect Dis. 2022;9(5):ofac090.
Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO studies.
Antimicrob Agents Chemother. 2018;62(4):e01919-17.
Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections.
N Engl J Med. 2014;370(23):2180-90.
Single-Dose Oritavancin versus 7-10 days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study.
Clin Infect Dis. 2015;60(2):254-62.

In Vitro Microbiology and Pharmacology Studies

Population Pharmacokinetic Analysis for a Single 1,200-milligram Dose of Oritavancin using data from Two Pivotal Phase 3 Clinical Trials.
Antimicrob Agents Chemother. 2015;59(6):3365-72.

Review Articles

Oritavancin (KIMYRSA™) in Acute Bacterial Skin and Skin Structure Infections: A Profile of its Use in the USA.
Drugs & Therapy Perspectives. 2022;38:57-63.

Real-World Studies and Analyses

Comparison of Inpatient Standard-of-Care to Outpatient Oritavancin Therapy for Patients with Acute Uncomplicated Cellulitis.
J Pharm Pract. 2021;36(1):27-32.
Improved Economic and Clinical Outcomes with Oritavancin versus a Comparator Group for Treatment of Acute Bacterial Skin and Skin Structure Infections in a Community Hospital.
PLoS One. 2021;16(3):e0248129.
Early directed Oritavancin therapy in the Emergency Department may lead to Hospital Avoidance compared to Standard Treatment for Acute Bacterial Skin and Skin Structure Infections: A Real-World Retrospective Analysis.
Drugs Real World Outcomes. 2020;7:20-29.
Expediting Discharge in Hospitalized, Adult Patients with Skin and Soft Tissue Infections who received Empiric Vancomycin Therapy with Oritavancin: Description of Findings from an Institutional Pathway.
Drugs Real World Outcomes. 2020;7:30-35.
Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs between patients who were Treated with Oritavancin or Vancomycin for a Skin Infection in the Outpatient setting.
Open Forum Infect Dis. 2019;6(12):ofz475.

Presentations

IDWeek 2023

Trend Analysis of Oritavancin and Comparator Agents Activity against Enterococcus Causing Infections in US Medical Centers between 2017-2019 and 2022. Poster 734.
Comparative Activity of Oritavancin and Comparator Agents against Staphylococcus aureus and Streptococcus spp. Causing Skin and Skin Structure Infections in US Medical Centers between 2017-2019 and 2022. Poster 1812.

IDWeek 2021

Oritavancin Activity Against Methicillin-Resistant S. aureus (MRSA) Isolates Causing Skin and Skin Structure Infections in US Hospitals (2017-2019). Poster 1369.

 See full Prescribing Information

Manuscripts

Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection Following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN).
Antimicrob Agents Chemother. 2021;65(3):e01809-20.

Presentations

IDWeek 2021

High Dose Minocycline for the Treatment of Acinetobacter Infections. Poster 1283.

 See full Prescribing Information

Manuscripts

Registrational and Pivotal Trial Data

A Phase 3 Study to Compare Delafloxacin with Moxifloxacin for the Treatment of Adults with Community-Acquired Bacterial Pneumonia (DEFINE-CABP).
Open Forum Infect Dis. 2019;7(1):ofz514.
Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial.
Antimicrob Agents Chemother. 2020;97:374-379.
A Randomized, Double-Blind, Phase 2 Study to Evaluate Subjective and Objective Outcomes in Patients with Acute Bacterial Skin and Skin Structure Infections Treated with Delafloxacin, Linezolid or Vancomycin.
J Antimicrob Chemother. 2016;71(3):821-9.
Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
Clin Infect Dis. 2019;68(Suppl 3):S233-S240.
Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
Clin Infect Dis. 2019;68(Suppl 3):S223-S232.
Efficacy of Delafloxacin Versus Moxifloxacin against Atypical Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
Int J Infect Dis. 2020;97:374-379.
A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin with Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.
Clin Infect Dis. 2018;67(5):657-666.

In Vitro Microbiology and Pharmacology Studies

In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections.
Antimicrob Agents Chemother. 2017;61(9):e00772-17.

Review Articles

Delafloxacin: A Review in Community-Acquired Pneumonia.
Drugs. 2022;82(8):913-923.
Community-Acquired Bacterial Pneumonia-Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin.
Clin Drug Investig. 2020;40(10):947-960.
Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.
Drugs. 2020;80(12):1247-1258.

Real-World Studies and Analyses

Update on the Activity of Delafloxacin against Acute Bacterial Skin and Skin-Structure Infection Isolates from European Hospitals (2014-2019).
J Glob Antimicrob Resist. 2020;23:278-283.
Comparative Efficacy of Delafloxacin for Complicated and Acute Bacterial Skin and Skin Structure Infections: Results from a Network Meta-Analysis.
BMC Infect Dis. 2021;21:1036.

Presentations

IDWeek 2023

Delafloxacin and Comparator Fluoroquinolone In Vitro Resistance Trends in Isolates from Skin and Skin Structure Infections in the USA (2017-2022). Poster 2754.

IDWeek 2019

Delafloxacin Activity against Drug-Resistant Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis from US Medical Centers (2014-2018). Poster 1582.
External links on this page are not affiliated with CorMedix Therapeutics. Links to sites outside of CorMedix are provided as a resource to the viewer. CorMedix accepts no responsibility for the content of linked sites. The publications above are intended to share pertinent data regarding CorMedix products and associated disease states. The views expressed by the authors are their own, and do not necessarily represent those of CorMedix.